Phase 1 Recurrent Glioblastoma Clinical Trials
24 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 24 trials
Recruiting
Phase 1
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more
Northwestern University30 enrolled1 locationNCT06410248
Recruiting
Phase 1
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 1Phase 2
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Recurrent Glioblastoma, IDH-WildtypeRecurrent MGMT-Methylated Glioblastoma
National Cancer Institute (NCI)97 enrolled36 locationsNCT05432804
Recruiting
Phase 1
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting
Phase 1
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled42 locationsNCT06860594
Recruiting
Phase 1
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Resectable GlioblastomaIDH Wildtype GlioblastomaRecurrent Astrocytoma+2 more
Jonsson Comprehensive Cancer Center10 enrolled1 locationNCT07089641
Recruiting
Phase 1
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-WildtypeAstrocytoma, Grade IV
Mayo Clinic20 enrolled1 locationNCT05789394
Recruiting
Phase 1
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 1
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Phase 1
CUE-102 in Recurrent Glioblastoma
GlioblastomaGlioma, MalignantRecurrent Glioblastoma
David Reardon, MD18 enrolled2 locationsNCT06917885
Recruiting
Phase 1
CARv3-TEAM-E T Cells in Glioblastoma
GlioblastomaMalignant GliomaRecurrent Glioblastoma+1 more
Marcela V. Maus, M.D.,Ph.D.21 enrolled1 locationNCT05660369
Recruiting
Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Recurrent Glioblastoma MultiformePrimary Glioblastoma MultiformeBrain Neoplasms, Malignant+1 more
AstraZeneca180 enrolled12 locationsNCT03423628
Recruiting
Phase 1Phase 2
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
Recurrent GlioblastomaRecurrent Gliosarcoma
M.D. Anderson Cancer Center6 enrolled1 locationNCT05039281
Recruiting
Phase 1
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Recurrent Glioblastoma
University of Pennsylvania12 enrolled1 locationNCT07209241
Recruiting
Phase 1
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
Recurrent GlioblastomaRefractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University14 enrolled1 locationNCT07193628
Recruiting
Phase 1
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
GlioblastomaRecurrent Glioblastoma
Nicholas Butowski48 enrolled1 locationNCT05557292
Recruiting
Phase 1
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
Recurrent GlioblastomaRefractory Glioblastoma
City of Hope Medical Center60 enrolled1 locationNCT04003649
Recruiting
Phase 1
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Recurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma
City of Hope Medical Center27 enrolled1 locationNCT06815029